View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsTradeUP Acquisition 将来の成長Future 基準チェック /06現在、 TradeUP Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.8m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (US$16.9m market cap).お知らせ • May 17TradeUP Acquisition Corp. announced delayed 10-Q filingOn 05/16/2023, TradeUP Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 04Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction.Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction on September 30, 2022. Pursuant to the agreement, stockholders of Estrella immediately prior to the Effective Time collectively will receive from UPTD, in the aggregate, a number of newly issued shares of common stock of UPTD, equal to: (i) $325 million (the “ Merger Consideration ”), divided by (ii) $10.06 per share. The pro forma equity valuation (assuming no redemptions) of Estrella Immunopharma is expected to be approximately $398.5 million. Upon the closing of the transaction, TradeUP’s public stockholders would retain an ownership interest of approximately 11.1% in Estrella Immunopharma, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of Estrella Immunopharma, and the Estrella stockholders will own approximately 81.6% of Estrella Immunopharma. Upon closing of the transaction, Estrella shall become a publicly listed company and TradeUP will be renamed “Estrella Immunopharma, Inc.” Estrella’s President and Chief Executive Officer, Cheng Liu and the current management team will continue to lead Estrella Immunopharma. Cheng Liu will also continue in his role as President and Chief Executive Officer of Eureka. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction. The transaction will require the approval of the stockholders of TradeUP, the applicable waiting periods, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or terminated, the net tangible assets upon the consummation with the deal no less than $5,000,0001, the deal Consideration Shares having been approved for listing on Nasdaq, an aggregate of at least $20 million cash including (a) the amount of cash available in the Trust Account immediately prior to the Closing, completion of transaction financing prior to or at the closing of at least $20 million by UPTD and is subject to other customary closing conditions including the receipt of certain regulatory approvals. The deal is expected to close in the first half of 2023. Estimated cash proceeds to Estrella Immunopharma from the transaction are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions). US Tiger Securities, Inc. has acted as financial advisor to TradeUP. Arila Zhou and Anna Jinhua Wang of Robinson & Cole LLP acted as legal advisor to TradeUP. Mike Blankenship, James Brown and Louis Savage of Winston & Strawn LLP acted as legal advisor to Estrella. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、TradeUP Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:UPTD - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2023N/A-1-1-1N/A3/31/2023N/A-1-1-1N/A12/31/2022N/A-1-1-1N/A9/30/2022N/A-1-1-1N/A6/30/2022N/A-1-1-1N/A3/31/2022N/A000N/Aアナリストによる今後の成長予測収入対貯蓄率: UPTDの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: UPTDの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: UPTDの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: UPTDの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: UPTDの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: UPTDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/04 09:53終値2023/09/29 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TradeUP Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.8m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (US$16.9m market cap).
お知らせ • May 17TradeUP Acquisition Corp. announced delayed 10-Q filingOn 05/16/2023, TradeUP Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 04Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction.Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction on September 30, 2022. Pursuant to the agreement, stockholders of Estrella immediately prior to the Effective Time collectively will receive from UPTD, in the aggregate, a number of newly issued shares of common stock of UPTD, equal to: (i) $325 million (the “ Merger Consideration ”), divided by (ii) $10.06 per share. The pro forma equity valuation (assuming no redemptions) of Estrella Immunopharma is expected to be approximately $398.5 million. Upon the closing of the transaction, TradeUP’s public stockholders would retain an ownership interest of approximately 11.1% in Estrella Immunopharma, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of Estrella Immunopharma, and the Estrella stockholders will own approximately 81.6% of Estrella Immunopharma. Upon closing of the transaction, Estrella shall become a publicly listed company and TradeUP will be renamed “Estrella Immunopharma, Inc.” Estrella’s President and Chief Executive Officer, Cheng Liu and the current management team will continue to lead Estrella Immunopharma. Cheng Liu will also continue in his role as President and Chief Executive Officer of Eureka. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction. The transaction will require the approval of the stockholders of TradeUP, the applicable waiting periods, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or terminated, the net tangible assets upon the consummation with the deal no less than $5,000,0001, the deal Consideration Shares having been approved for listing on Nasdaq, an aggregate of at least $20 million cash including (a) the amount of cash available in the Trust Account immediately prior to the Closing, completion of transaction financing prior to or at the closing of at least $20 million by UPTD and is subject to other customary closing conditions including the receipt of certain regulatory approvals. The deal is expected to close in the first half of 2023. Estimated cash proceeds to Estrella Immunopharma from the transaction are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions). US Tiger Securities, Inc. has acted as financial advisor to TradeUP. Arila Zhou and Anna Jinhua Wang of Robinson & Cole LLP acted as legal advisor to TradeUP. Mike Blankenship, James Brown and Louis Savage of Winston & Strawn LLP acted as legal advisor to Estrella.